Population-based Laboratory Surveillance for AmpC β-Lactamase–producing Escherichia coli, Calgary by Pitout, Johann D.D. et al.
In the Calgary Health Region during 2000–2003,
prospective, active, population-based laboratory surveil-
lance for all cefoxitin-resistant Escherichia coli isolates was
performed. Isolates were screened with an inhibitor-based
disk test, and plasmid-mediated types were identified by
multiplex PCR with sequencing. A total of 369 AmpC β-lac-
tamase–producing E. coli isolates were identified; annual
incidence rates were 1.7, 4.3, 11.2, and 15 per 100,000
residents for each year, respectively. AmpC β-
lactamase–producing E. coli was 5× more likely to be iso-
lated from female than male patients across all age groups
except <1 year. Of these isolates, 83% were community
onset, and urine was the principal site of isolation (90% of
patients). PCR showed that 125 (34%) were positive for
blacmy genes; sequencing identified these enzymes to be
CMY-2. In this large Canadian region, AmpC β-lacta-
mase–producing  E. coli is an emerging community
pathogen that commonly causes urinary tract infections in
older women.
O
rganisms that produce plasmid-mediated AmpC β-
lactamases were first reported in the 1980s (1). These
β-lactamases are derivatives of the chromosomally encod-
ed clavulanate-resistant AmpC cephalosporinases of bacte-
ria such as Enterobacter  spp., Citrobacter freundii,
Morganella morganii, Aeromonas spp., and Hafnia alvei
(2). These enzymes have been reported in Escherichia coli,
Klebsiella pneumoniae,  K. oxytoca,  Salmonella spp.,
Enterobacter aerogenes, and Proteus mirabilis. Because
the genes are typically encoded on large plasmids that con-
tain additional antimicrobial resistance genes, therapeutic
options are limited (3).
E. coli possess a chromosomal gene that encodes for
an AmpC β-lactamase. Usually, low amounts of β-lacta-
mases are produced because the AmpC gene is regulated
by a weak promoter and a strong attenuator. These E. coli
isolates are sensitive to the cephamycins (4). However,
surveys of resistance mechanisms in cephamycin-resistant
isolates have identified promoter or attenuator mutations
that result in the upregulation of AmpC β-lactamase pro-
duction; these isolates are referred to as AmpC hyperpro-
ducers (5). Occasionally, cephamycin-resistant strains
produce plasmid-mediated β-lactamases such as CMY-2,
which are derived from bacteria with chromosomally
encoded AmpC cephalosporinases (3). In addition, altered
expression of outer membrane proteins constituting porins
can also contribute to cephamycin resistance (6).
Methods for detecting E. coli AmpC hyperproducers
or isolates that produce plasmid-mediated cephalospori-
nases are technically demanding for clinical laboratories.
Although nonsusceptibility to the cephamycins suggests
increased production of AmpC β-lactamases, organisms
that produce these types of enzymes often go undetected
and have been responsible for several nosocomial out-
breaks (2,7).
Surveillance studies of organisms that produce plas-
mid-mediated AmpC β-lactamases, especially among com-
munity isolates, are needed (8). We noticed an increase in
cephamycin-resistant E. coli isolates in the Calgary Health
Region (CHR) during 2002 and 2003 (from 0.1% of all E.
coli isolated in 2000 to 1.3% in 2003). To our knowledge,
no surveillance studies have investigated the population-
based epidemiology of AmpC β-lactamase–producing E.
coli (i.e., hyperproducers or plasmid-mediated enzymes),
although studies have shown the widespread distribution of
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objectives were to define the population-based incidence of
infections caused by E. coli that produce increased levels of
AmpC  β-lactamases in a large well-defined Canadian
region and investigate whether plasmid-mediated types
were present in this population.
Methods
Patient Population
CHR provides all publicly funded healthcare services
to the >1 million persons residing in the cities of Calgary
and Airdrie and numerous adjacent surrounding communi-
ties covering an area of 37,000 km2 (www.health.gov.
ab.ca/regions/RHA_comm3.html). Acute care is provided
mainly through 1 pediatric hospital and 3 large hospitals
for adults. A centralized laboratory (Calgary Laboratory
Services; CLS) performs the routine clinical microbiology
services for the community, e.g., nursing homes, physi-
cians’ offices, community collection sites (where outpa-
tients submit specimens for investigation purposes), and
hospital sites within the CHR. Our base study population
consisted of all patients from whom cefoxitin-resistant E.
coli was first identified by CLS from January 1, 2000,
through December 31, 2003.
Population-based Surveillance.
Prospective, active, population-based, laboratory sur-
veillance for all cefoxitin-resistant E. coli isolates was per-
formed by CLS; all cefoxitin-resistant E. coli isolates were
included in this study. We used the laboratory information
system at CLS (PathNet Classic version 306, Cerner,
Kansas City, MO, USA) to determine basic demographic
information (age, sex, specimen submission site, date of
hospital admission) and microbiologic data (location of
isolate on patient and antimicrobial-susceptibility testing
results) for all patients. Isolates were frozen and stored in
batches for further analyses. Community-onset isolates
were the first cultures obtained from outpatients or inpa-
tients within 2 days of hospital admission. Hospital-onset
isolates were the first cultures taken >2 days after admis-
sion to a hospital.
Clinical Microbiology and Molecular 
Laboratory Testing
We included consecutive nonduplicate isolates of E.
coli that were intermediately resistant or resistant to cefox-
itin (MIC>8 µg/mL) and that were collected at CLS during
January 2000 through December 2003 and isolated from
clinical specimens by standard microbiology techniques.
During June 2001, we cultured urine samples that had pos-
itive screening results from an ATPase-luciferase assay
and those specifically requested by a physician (12).
Strains were identified to the species level by using Vitek
(Vitek AMS; bioMérieux Vitek Systems Inc., Hazelwood,
MO, USA.). MICs to the following drugs were determined
by Vitek: imipenem, gentamicin, tobramycin, trimetho-
prim-sulfamethoxazole, and ciprofloxacin. Results were
interpreted according to the Clinical and Laboratory
Standards Institute criteria for broth dilution (13).
Clinical isolates of cefoxitin-resistant E. coli were
tested for AmpC β-lactamases by using the combination of
the AmpC β-lactamase inhibitor Syn 2190 and cefotetan
disks as described (14). All isolates with an AmpC β-lacta-
mase were further investigated for plasmid-mediated
AmpC β-lactamase genes by using multiplex PCR condi-
tions and primers as described (15). These included
enzymes that originated from the chromosomally encoded
AmpC cephalosporinases of bacteria. Genes of the CMY-
positive isolates were identified by cycle sequencing the
full-length amplified products with conditions and differ-
ent primers as described (16).
Analysis
All analyses were performed by using Stata version
9.0 (Stata Corp., College Station, TX, USA). Variables
were assessed before analysis by using histograms to iden-
tify underlying distribution. Means with standard devia-
tions were used to describe normally or near normally
distributed variables and were compared by using the
Student t test. Medians with interquartile ranges (IQRs)
were used to describe nonnormally distributed variables
and were compared by using the Mann-Whitney U test.
Differences in proportions were compared by using the
Fisher exact test. Incidence rates (per 100,000 population
per year) were calculated by using the annual number of
new cases among CHR residents as the numerator and
regional population estimates for each year from 2000
through 2003 (December 2003 boundaries) of the CHR as
the denominator. Patients with Alberta healthcare numbers
were considered CHR residents and were included; those
with out-of-province healthcare numbers were excluded.
Age- and sex-specific incidence rates were calculated by
dividing the number of new cases within a subgroup by the
population at risk. Risk ratios (RR) for incidence rates
among demographic subgroups were calculated by divid-
ing the incidence rate with the factor (as opposed to with-
out) and were reported with 95% confidence intervals
(CIs) as described (17).
Results
During the 4-year study period, 78,275 E. coli isolates
were obtained from 51,735 patients; 72,756 (93%) isolates
were classified as community onset and 5,519 (7%) as hos-
pital onset. For 408 (0.7%) patients, a cefoxitin-resistant E.
coli isolate was identified. The number of isolates (per first
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year: 23 (0.1%) of 17,989 patients in 2000, 53 (0.3%) of
15,907 in 2001, 141 (1%) of 14,583 in 2002, and 191
(1.3%) of 14,319 in 2003 (p<0.0001 for 2000 compared
with 2003). Of the 408 cefoxitin-resistant isolates, 384
(94%) were available for further analysis. Of these, 369
(96%) were positive for AmpC β-lactamases according to
the Syn 2190 inhibitor disk screen test, and of the 369, 359
(97%) were from CHR residents. The number of isolates
identified in CHR residents during 2000, 2001, 2002, and
2003 were 18, 46, 123, and 172, with annualized incidence
rates of 1.7, 4.3, 11.2, and 15 per 100,000, respectively.
Seasonal variability in the occurrence of AmpC β-lac-
tamase–producing E. coli isolates was moderate; the low-
est rates of isolation were in early winter and spring, and
the highest rates were in late summer and fall (Figure 1).
Of the 369 isolates, 61 (17%) were classified as hospital
onset. Of the 308 (83%) community-onset isolates, 54
were submitted from hospital emergency departments, 24
from inpatients within the first 2 days of admission, 20
from nursing home residents, and the rest from outpatients.
While the number of hospital-onset AmpC β-
lactamase–producing E. coli isolates increased gradually
during 2000–2003 (5, 12, 20, 24 each year, respectively),
the number of community-onset isolates increased dramat-
ically (13, 35, 108, 152 each year, respectively). The
increase among the acute care centers was not the result of
clustering of patients in a specific acute care center.
However, in relation to all first E. coli isolates per year per
patient tested by CLS, AmpC β-lactamase–producing E.
coli were proportionally more likely to be obtained as hos-
pital-onset isolates (Figure 2).
The median age of the cohort was 51.1 (IQR
27.3–74.3) years; most (310; 84%) patients were female.
Incidence of AmpC β-lactamase–producing E. coli signif-
icantly increased in association with increasing age
(Figure 3). Risk for isolation of AmpC β-lactamase–pro-
ducing E. coli was 5× higher for female than male resi-
dents (14.0 vs. 2.6 per 100,000 per year; RR 5.4; 95% CI
4.04–7.31; p<0.0001); this increased risk was observed
across all age groups with the exception of the very young
(< 1 year) (Figure 3).
Among the 369 AmpC β-lactamase–producing iso-
lates, the principal site of isolation was the urinary tract for
333 (90%) patients, bloodstream for 20 (5%), respiratory
tract for 8 (2%), soft tissue for 5 (1%), and abdomen for 3
(1%). Of these same 369 isolates, 73 (20%) were not sus-
ceptible to trimethoprim-sulfamethoxazole, 32 (9%) to
tobramycin, 54 (14%) to gentamicin, and 33 (9%) to
ciprofloxacin. No resistance to imipenem was detected.
Multiplex PCR amplified a 462-bp amplicon among
125 (34%) of the 369 AmpC β-lactamase–producing
isolates that was consistent with the plasmid-encoded
types of AmpC β-lactamases originating from the chromo-
somal gene of Citrobacter freundii (CMY types) (15). No
other types of plasmid-mediated AmpC enzymes were
present. Sequence analysis of full-length PCR products on
15 randomly selected isolates showed 100% identity to
blaCMY-2 (18). The Table shows features of CMY-type and
non–CMY-type AmpC β-lactamases. With the exception
of a higher rate of gentamicin resistance among CMY-
2–positive strains (Table), E. coli isolates that produced
CMY-types and those that produced non-CMY types of
AmpC β-lactamases did not differ according to year of
study, principal site of isolation, or demographics.
Conclusion
Limited data are available regarding hyperproduction
of AmpC β-lactamases among E. coli in the United States
AmpC β-Lactamase–producing E. coli 
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Figure 1. AmpC β-lactamase–producing Escherichia coli isolates
per 1,000 E. coli isolates, Calgary Health Region, 2000–2003.
Data are averaged over the 4-year period. The presence of plas-
mid-mediated AmpC β-lactamase genes was determined by using
multiplex PCR conditions and primers as described (8). CMY; iso-
lates positive for chromosomal gene of Citrobacter freundii; non-
CMY; isolates negative by multiplex PCR. 
Figure 2. First AmpC β-lactamase–producing Escherichia coli iso-
lates per 1,000 E. coli isolates per year. Calgary Health Region,
2000–2003. Community isolates were those obtained from outpa-
tients or admitted patients who had their first cultures obtained
within 2 days of hospital admission. First cultures from other hos-
pitalized patients obtained after 2 days of admission were deemed
to represent hospital-onset isolates.and Canada. A study from Canada showed that most
cephamycin-resistant E. coli from the Toronto area in 2001
had different promoter and attenuator mutations in the
chromosomal AmpC cephalosporinases (5). Jacoby and
colleagues found plasmid-mediated AmpC-type resistance
in 7 of 75 of ceftazidime-resistant E. coli from 25 US
states; 2 of these isolates produced CMY-2 (19). Mulvey
and colleagues studied 232 cefoxitin-resistant E. coli from
12 hospitals in Canada and found that 25 (11%) strains
contained CMY-2 and 51 (22%) had different promoter
and attenuator mutations (20). E. coli that produce CMY-2
have also had been isolated from food-producing animals
in Canada and the United States (21,22).
Laboratory tests that use inhibitors of AmpC β-lacta-
mases in E. coli successfully distinguish between isolates
that have altered expression of outer membrane proteins
and isolates that produce increased levels of AmpC β-lac-
tamases (23,24). Multiplex PCR that detects the different
types of plasmid-mediated AmpC β-lactamases is the most
practical way to differentiate between isolates with pro-
moter or attenuator mutations and those with plasmid-
mediated cephalosporinases (15). Our study screened all
cefoxitin-resistant E. coli for AmpC β-lactamases and used
multiplex PCR to identify plasmid-mediated types.
However, the cephalosporinases that originated from H.
alvei (e.g., ACC types) are not detected by our phenotypic
method. In our study, >90% of cefoxitin-resistant strains
produced increased levels of AmpC cephalosporinases;
125 (34%) of these 369 were positive for CMY-2, much
higher than the 11% reported by Mulvey et al. (20). None
of the other plasmid-mediated AmpC types were present in
E. coli isolated from patients in the CHR.
Some studies have recognized a role of AmpC β-lac-
tamase–producing E. coli in nosocomial infections (2,3,7);
however, these studies were based at institutions and did
not survey community-based laboratories. Because our
surveillance included all clinical specimens from hospital
and community sites, we are highly unlikely to have
missed many isolates. We observed that in the CHR,
AmpC β-lactamase–producing E. coli is predominantly a
community-onset pathogen. The designs of other studies in
the literature (19,20) make it unclear whether AmpC β-lac-
tamase–producing E. coli is an important cause of commu-
nity-onset infections elsewhere. A community outbreak in
CHR during 2002 resulted from CMY-2–producing
Salmonella enterica serotype Newport associated with the
handling of pet treats (25). A previous study from our cen-
ter has shown that these salmonella isolates share similar-
size plasmids with CMY-2–producing E. coli of multiple
pulsed-field gel electrophoresis types identified in our
study (D.B. Gregson, unpub. data). Thus, E. coli and
Salmonella spp. may share similar plasmids.
Several investigations have shown that animals may
represent a source for dissemination of AmpC-encoding
genes from E. coli to humans. Evidence of CMY-2–produc-
ing isolates in cattle (26), pork (27), poultry (21,28), and
dogs and cats (29) is of concern because food-producing
animals and domestic pets may act as reservoirs for resist-
ant organisms. Therefore, factors that lead to the high rate
of isolation of AmpC β-lactamase–producing  E. coli in
patients from the community require further exploration.
Ours is the first report of the population epidemiology
of AmpC β-lactamase–producing E. coli. We restricted our
study to E. coli because other plasmid-mediated AmpC-
producing organisms are rare in our region (only 17
patients infected with AmpC-producing K. pneumoniae
and 12 with AmpC-producing Salmonella spp. were iden-
tified at CLS during this study period). We determined
demographic risk factors associated with the isolation of
AmpC  β-lactamase–producing  E. coli by comparing
patient demographic characteristics with our well-defined
base population. In these analyses, female and older
patients were at much higher risk than male and younger
patients (Figure 3). These results are similar to those we
obtained in a previous study from CHR that investigated
the population epidemiology of infections caused by
extended-spectrum β-lactamase (ESBL)–producing E. coli
during 2000–2002 (30). Incidence of ESBL-producing iso-
lates was stable for the 3 years; incidence rates in 2000,
2001, and 2002 were 5.0, 5.6, and 5.7 per 100,000, respec-
tively. These rates differ from those for AmpC β-lacta-
mase–producing E. coli in this study, which had rates of
1.7, 4.3, and 11.2 per 100,000 for these 3 years, respective-
ly. Our previous study also showed that most ESBL-pro-
ducing E. coli from our region isolated during the same
period were resistant to gentamicin and ciprofloxacin (30);
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mase–producing isolates were resistant to gentamicin and
ciprofloxacin, respectively. Thus, susceptibility patterns
differ between ESBL- and AmpC β-lactamase–producing
E. coli from the CHR isolates during the same period.
The population-based design has some methodologic
limitations. First, because this was a laboratory-based
study, detailed clinical information (e.g., prior receipt of
antimicrobial drugs, travel, exposure to food and water,
underlying concurrent conditions) was not available. We
were therefore unable to determine whether the isolates in
this study truly caused infection. The lack of detailed clin-
ical information is an inherent limitation to all laboratory-
based studies. Second, isolates were defined as either
community- or hospital-onset on the basis of their location
of submission. Although this may in part reflect where
these organisms were acquired, some isolates classified as
community onset may have been associated with health-
care (31). Third, incidence rates were based on the
assumption that all persons with Alberta healthcare num-
bers were CHR residents. We estimate that 10%–15% of
patients in this study may have resided within other health
regions in Alberta rather than within CHR. As a result, our
incidence rates may be slightly higher than the true values.
In conclusion, this study demonstrates that AmpC
β-lactamase–hyperproducing E. coli is an emerging com-
munity pathogen in the CHR with public health implica-
tions. Our results warrant increased efforts at surveillance
for and the study of risk factors associated with the acqui-
sition of these isolates in order to guide future prevention
and control measures
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